Rausch, Caitlin R <br/><br/>
Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management.  [electronic resource] 

 -  Cancer  03 2020 
 - 1152-1160 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1097-0142 
<br/><br/><label>Standard No.: </label>10.1002/cncr.32606  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Age Factors<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Brain Neoplasms--prevention & control<br/>Constipation--chemically induced<br/>Cyclophosphamide--administration & dosage<br/>Cytarabine--administration & dosage<br/>Dexamethasone--administration & dosage<br/>Doxorubicin--administration & dosage<br/>Drug Monitoring--methods<br/>Fusion Proteins, bcr-abl--antagonists & inhibitors<br/>Genetic Predisposition to Disease<br/>Humans<br/>Injections, Spinal<br/>Intercellular Signaling Peptides and Proteins--therapeutic use<br/>Kidney--drug effects<br/>Methotrexate--administration & dosage<br/>Ophthalmic Solutions--administration & dosage<br/>Peripheral Nervous System Diseases--chemically induced<br/>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma--drug therapy<br/>Precursor Cell Lymphoblastic Leukemia-Lymphoma--drug therapy<br/>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma--drug therapy<br/>Prednisone--administration & dosage<br/>Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Vincristine--administration & dosage